Stocks and Investing Stocks and Investing
Mon, December 6, 2021
Sat, December 4, 2021
Fri, December 3, 2021
Thu, December 2, 2021
Wed, December 1, 2021

Robyn Karnauskas Maintained (VRTX) at Strong Buy with Increased Target to $341 on, Dec 1st, 2021


Published on 2024-10-27 18:49:37 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $331 to $341 on, Dec 1st, 2021.

Robyn has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
  • Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 4 analyists that currently disagree with Robyn


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Wednesday, November 3rd, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021